M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
The most notable increase was Solventum Corp (NYSE:SOLV), with an additional 1,336,564 shares, bringing the total to 8,462,819 shares. This adjustment represents a significant 18.76% increase in share ...
Nelson Peltz’s Trian Partners sent a letter to the shareholders of Solventum (SOLV), saying the company trades at a discount to peers and 3M (MMM), Scott Wapner of CNBC reports. Trian believes ...
Nelson Peltz’s Trian Fund Management disclosed in an SEC filing its holdings as of December 31, 2024. Trian increased its stake in a number of ...
Solventum Shares Are Up Today ... its bioproduction portfolio with expected long-term growth. Vandana Singh Nelson Peltz's Trian Fund Management Reshaped Portfolio Ahead Of Presidential Election ...
Unilever's board, which includes billionaire activist investor Nelson Peltz, was unified in its decision to oust CEO Hein ...
Thermo Fisher Scientific said Tuesday it is buying Solventum’s purification and filtration business, confirming an earlier ...